At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 12, 2026 at 16:30 ET
Azitra reported a Q3 2026 net loss of $3.0M ($0.29 per share), wider than the $2.8M loss a year ago, with cash of $3.8M. The key catalysts are upcoming topline data from the ATR-04 Phase 1/2 trial (Cohort 1) and initial results from the ATR-COSF first-in-human cosmetic study, both expected by year-end 2026. The company also noted that institutional investors may invest an additional $5.25M to $10.5M after the ATR-COSF results are announced.
- Net loss of $3.0M for Q3 2026, compared to $2.8M in Q3 2025
- Cash and cash equivalents of $3.8M as of September 30, 2026
- ATR-04 Phase 1/2 trial completed Cohort 1; safety committee recommended proceeding to Cohort 2
- Topline data from ATR-04 Cohort 1 expected in Q4 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access